Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GSK SCLC drug ‘provides convenient alternative to IV therapy’

GSK SCLC drug ‘provides convenient alternative to IV therapy’

16th October 2007

GlaxoSmithKline (GSK) has reported that Hycamtin (topotecan), its recently-approved orally-administered treatment for the treatment of relapsed small cell lung cancer (SCLC), offers patients an alternative to intravenous (IV) therapy.

The company announced that the drug had received approval from the US Food and Drug Administration (FDA) earlier this week, with the product due to be launched in 2008.

Hycamtin is indicated in patients who have exhibited a complete or partial response to first-line treatment with chemotherapy and are a minimum of 45 days from the end of this treatment.

The compound inhibits the naturally-produced protein topoisomerase I that is necessary for cell division in cancer cells and normal body cells.

Debasish Roychowdhury, vice-president of global clinical development at the oncology medicine development centre at GSK, said: “The approval of Hycamtin capsules is particularly important for patients with relapsed small cell lung cancer as they now have an effective treatment option that has been shown to provide a survival benefit and can be conveniently taken at home.”

He added that this approval highlights the dedication of the company to improving patient quality of life in the field of oncology.

In June 2006, GSK reported that Hycamtin received a new indication from the FDA, the compound being approved as a treatment for cervical cancer.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.